Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPEx in first-line metastatic or recurrent HNSCC
NCT01289522Phase 2Completed
- Sponsor
- GORTEC
- Start
- Sep 2009
- Primary completion
- Jan 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of KL-140, docetaxel, Cisplatin micelle injection (HA132) in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Sep 2009; status: completed.
02
Drugs
KL-140docetaxelCisplatin micelle injection (HA132)
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01289522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01289522.